- Home
- RCKY vs IPHA Comparison
RCKY vs IPHA Comparison
Compare RCKY & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RCKY | IPHA |
|---|---|---|
| Founded | 1932 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.3M | 174.2M |
| IPO Year | 1993 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RCKY | IPHA |
|---|---|---|
| Price | $29.07 | $1.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $40.00 | $5.00 |
| AVG Volume (30 Days) | 56.1K | ★ 565.3K |
| Earning Date | 10-28-2025 | 09-17-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 53.66 | N/A |
| EPS | ★ 2.74 | N/A |
| Revenue | ★ $470,314,000.00 | $14,839,695.00 |
| Revenue This Year | $7.09 | $22.29 |
| Revenue Next Year | $4.27 | $43.90 |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | ★ 4.13 | N/A |
| 52 Week Low | $11.93 | $1.47 |
| 52 Week High | $33.40 | $3.51 |
Technical Indicators
Market Signals| Indicator | RCKY | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 48.48 |
| Support Level | $28.68 | $1.85 |
| Resistance Level | $30.80 | $1.96 |
| Average True Range (ATR) | 1.11 | 0.07 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 16.21 | 56.67 |
Price Performance
Historical ComparisonAbout RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.